secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2021-11-22T23:59:59+00:00
Accession:  0001193125-21-335921
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab appoints Richard Gaynor, MD as independent director and R&D Committee chair
--------------------------------------------------------------------------------

- Gaynor is President & Chief R&D Officer at BioNTech US; previously 15 years at Lilly Oncology.
- He receives $50K annual cash retainer for Board, plus $10K as R&D Committee chair, pro-rated to $6,904 for 2021.
- Gaynor received an initial grant of 8,912 restricted ordinary shares on November 19, 2021.
- CEO Samantha Du noted Gaynor and Scott Morrison were added to the Board in the past two months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000119312521335921/0001193125-21-335921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000119312521335921/d244462d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-335921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer